Physician profile
Felix E Herrera
NPI 1699869461
$1,971.64
in general payments reported to CMS, 2019-2025
14 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $27.75 · 2021: $93.12 · 2022: $355 · 2023: $261 · 2024: $410 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $494.29 | 2019-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $386.00 | 2019-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $173.34 | 2019-2022 | |
| Amgen INC. | $161.20 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $152.89 | 2024-2025 | Rexulti |
| Allergan, INC. | $145.34 | 2019 | |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $116.33 | 2025 | Glassia |
| Lilly USA, LLC | $84.39 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $57.77 | 2021 | |
| Abbott Laboratories | $34.89 | 2021-2022 | |
| Medtronic USA, INC. | $18.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.